Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration
-
Add time:07/20/2019 Source:sciencedirect.com
PurposeTo evaluate safety and efficacy of the angiostatic agent anecortave acetate, compared with a placebo, for treatment of subfoveal choroidal neovascularization (CNV).
We also recommend Trading Suppliers and Manufacturers of ANECORTAVE ACETATE RELATED COMPOUND A (20 MG) (9(11 )-DEHYDROCORTISOL) (cas 10184-70-0). Pls Click Website Link as below: cas 10184-70-0 suppliers
Prev:Pharmacokinetics and Metabolism of Anecortave Acetate in Animals and Humans
Next:Anecortave Acetate (15 Milligrams) versus Photodynamic Therapy for Treatment of Subfoveal Neovascularization in Age-Related Macular Degeneration) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Anterior Juxtascleral Delivery of Anecortave Acetate in Eyes with Primary Open-Angle Glaucoma: A Pilot Investigation07/23/2019
- Anecortave Acetate (15 Milligrams) versus Photodynamic Therapy for Treatment of Subfoveal Neovascularization in Age-Related Macular Degeneration07/22/2019
- Pharmacokinetics and Metabolism of Anecortave Acetate in Animals and Humans07/21/2019
- Preclinical Efficacy of Anecortave Acetate07/19/2019
